Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines
Jason I Couto1, Misty D Bear, Jiayuh Lin
1Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA.
Background:
STAT3 [1] has been shown to be dysregulated in nearly every major cancer, including osteosarcoma (OS). Constitutive activation of STAT3, via aberrant phosphorylation, leads to proliferation, cell survival and resistance to apoptosis. The present study sought to characterize the biologic activity of a novel allosteric STAT3 inhibitor, LLL12, in canine OS cell lines.
Results:
We evaluated the effects of LLL12 treatment on 4 canine OS cell lines and found that LLL12 inhibited proliferation, induced apoptosis, reduced STAT3 phosphorylation, and decreased the expression of several transcriptional targets of STAT3 in these cells. Lastly, LLL12 exhibited synergistic anti-proliferative activity with the chemotherapeutic doxorubicin in the OS lines.
Conclusion:
LLL12 exhibits biologic activity against canine OS cell lines through inhibition of STAT3 related cellular functions supporting its potential use as a novel therapy for OS.
Insights
A novel drug, LLL12, effectively targets Signal Transducer and Activator of Transcription 3 (STAT3) in canine osteosarcoma (OS) cells. LLL12 inhibits cancer cell growth and promotes cell death, showing promise as a new OS therapy.
Area of Science:
- Oncology
- Molecular Biology
- Veterinary Medicine
Background:
- Signal Transducer and Activator of Transcription 3 (STAT3) is frequently dysregulated in various cancers, including osteosarcoma (OS).
- Aberrant STAT3 activation promotes cancer cell proliferation, survival, and resistance to apoptosis.
- Canine osteosarcoma presents a relevant model for studying STAT3-targeted therapies.
Purpose of the Study:
- To investigate the biological activity of LLL12, a novel allosteric STAT3 inhibitor.
- To evaluate the efficacy of LLL12 in canine OS cell lines.
Main Methods:
- Treatment of four canine OS cell lines with LLL12.
- Assessment of cell proliferation, apoptosis, and STAT3 phosphorylation.
- Analysis of STAT3 transcriptional target gene expression.
- Evaluation of LLL12 in combination with doxorubicin.
Main Results:
- LLL12 significantly inhibited proliferation and induced apoptosis in canine OS cells.
- LLL12 reduced STAT3 phosphorylation and the expression of its target genes.
- LLL12 demonstrated synergistic anti-proliferative effects when combined with doxorubicin.
Conclusions:
- LLL12 demonstrates significant biological activity against canine OS cell lines by inhibiting STAT3 signaling.
- LLL12 effectively targets STAT3-dependent cellular functions in OS.
- LLL12 holds potential as a novel therapeutic agent for osteosarcoma treatment.
